Alopexx Secures Investment from Biotech Consortia, Inc.

On September 6, 2024, Alopexx, Inc., a biotechnology firm dedicated to the development of innovative, broad-spectrum immune-mediated treatments for bacterial, fungal, and parasitic infections, announced a significant investment from Biotech Consortia, Inc. (BCI).

The global crisis of antimicrobial resistance, primarily driven by the overuse and misuse of antibiotics, has led to the proliferation of antibiotic-resistant microorganisms. The financial support from BCI is expected to play a pivotal role in advancing Alopexx's flagship product, AV0328, along with other clinical initiatives within the company.

Dr. Daniel Vlock, CEO of Alopexx, expressed his enthusiasm about the investment, stating that it would bolster the company's entire product lineup. He emphasized the company's commitment to progressing the development of their broad-spectrum antimicrobial vaccine and other vaccines in the pipeline, with the aim of delivering life-saving solutions globally.

AV0328 is a synthetic vaccine that targets poly N-acetyl glucosamine (PNAG), a compound present on the surfaces of a diverse array of bacterial, fungal, and parasitic pathogens. Pre-clinical studies have demonstrated that targeting PNAG is effective in preventing and treating infections caused by more than 15 different pathogens. A completed Phase I, first-in-human trial revealed that AV0328 is well-tolerated, with no serious adverse effects reported. The vaccine successfully induced antibodies capable of neutralizing a wide range of PNAG-expressing pathogens, reinforcing its potential as a broad-spectrum antimicrobial agent. Additionally, AV0328 can be produced cost-effectively at approximately $1 per dose, making it an accessible option for low- and middle-income countries.

Alopexx's overarching mission is to develop immune therapeutics that prevent and treat bacterial, fungal, and parasitic infections. The company has identified PNAG as a target found in a variety of pathogens. Their vaccine candidate, AV0328, has shown promise in generating protective antibodies against many PNAG-expressing pathogens, as evidenced in a Phase I trial. Another product, F598, a fully human monoclonal antibody, has also demonstrated safety and tolerability in Phase I and pilot trials. A single infusion of F598 can offer protection for two to three months. Alopexx's goal is to create a broad-spectrum, non-antibiotic treatment platform for microbial infections, aiming to reduce dependency on antibiotics and curb the development of antimicrobial resistance.

BCI, an international business entity, concentrates on strategic investments, collaborations, and research and development in the biotechnology and pharmaceutical industries. This investment marks a significant milestone for Alopexx, enabling the company to further its mission of developing innovative solutions to combat microbial infections on a global scale.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!